RIA Advisory Group LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ – Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 31,036 shares of the company’s stock, valued at approximately $5,030,000. Johnson & Johnson comprises about 1.8% of RIA Advisory Group LLC’s portfolio, making the stock its 11th largest holding.
Other institutional investors have also recently made changes to their positions in the company. Innealta Capital LLC purchased a new position in Johnson & Johnson in the second quarter worth $27,000. Highline Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $31,000. Mowery & Schoenfeld Wealth Management LLC grew its stake in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares in the last quarter. Morton Brown Family Wealth LLC boosted its holdings in Johnson & Johnson by 400.0% in the 3rd quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock valued at $41,000 after purchasing an additional 200 shares during the last quarter. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $43,000. Institutional investors own 69.55% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of JNJ stock traded up $2.13 during trading hours on Friday, reaching $154.00. The stock had a trading volume of 11,328,515 shares, compared to its average volume of 7,017,128. The firm has a market capitalization of $370.77 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a 50-day simple moving average of $161.35 and a 200-day simple moving average of $156.02. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.
Insider Transactions at Johnson & Johnson
In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of research firms have issued reports on JNJ. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup raised their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.94.
Read Our Latest Analysis on JNJ
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- How to Calculate Return on Investment (ROI)
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- What is a Bond Market Holiday? How to Invest and Trade
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What is a Low P/E Ratio and What Does it Tell Investors?
- Time to Load Up on Home Builders?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.